학술논문
Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout
Document Type
article
Author
Source
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-11 (2023)
Subject
Language
English
ISSN
1478-6362
Abstract
Abstract Background While xanthine oxidase inhibitors target uric acid production, renal urate underexcretion is the predominant subtypes in gout. This study was to compare treatment response to the XOI febuxostat in a gout cohort according to clinical subtypes of hyperuricemia. Methods A prospective cohort study was conducted to compare the efficacy and safety of febuxostat (initially 20 mg daily, escalating to 40 mg daily if not at target) in 644 gout patients with the three major clinical subtypes for 12 weeks. Hyperuricemia was defined as the renal overload subtype, the renal underexcretion subtype, or the combined subtype based on UUE > or ≤ 600 mg/d/1.73 m2 and FEUA